Emerging data suggest Retatrutide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , could represent a significant step forward for body management . Initial https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026